Scope Fluidics

Scope Fluidics Acquisitions (Net)

The Acquisitions (Net) of Scope Fluidics (SCP.WA) as of Oct 31, 2026 is 95.46 M PLN. In the previous year, Acquisitions (Net) was -9.88 M PLN — a change of -1,066.71% (higher).

Acquisitions (Net)

95.46 MPLN

YoY

-1,066.71%

Last updated:

Acquisitions (Net) of Scope Fluidics is 2024 95.46 M PLN. Acquisitions (Net) of Scope Fluidics was 2023 -9.88 M PLN. It decreases by -1,066.71% higher compared to the previous year.

The Scope Fluidics Acquisitions (Net) history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Acquisitions (Net)
Date
Acquisitions (Net)
Jan 1, 2016
467,000.00 PLN
Jan 1, 2018
64,900.00 PLN
Jan 1, 2019
2.09 M PLN
Jan 1, 2020
-2.40 M PLN
Jan 1, 2021
-3.21 M PLN
Jan 1, 2022
372.42 M PLN
Jan 1, 2023
-9.88 M PLN
Jan 1, 2024
95.46 M PLN
The Scope Fluidics Acquisitions (Net) history
YEARAcquisitions (Net)YoY
95.46 MPLN-1,066.71%
-9.88 MPLN-102.65%
372.42 MPLN-11,687.55%
-3.21 MPLN+34.08%
-2.40 MPLN-214.85%
2.09 MPLN+3,115.72%
64,900.00PLN-86.10%
467,000.00PLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Scope Fluidics Stock analysis

What does Scope Fluidics do? Scope Fluidics SA generates revenue through the development and sale of disposable microfluidic systems for blood sample collection and reagent storage, targeting diagnostic and med-tech applications. The company's PCR ONE system detects bacterial and viral pathogens, while the BacterOMIC system provides data on bacterial susceptibility to antibiotics and resistance mechanisms. It offers laboratory access, workshops, and administrative services, including financing, to support its projects. Key clients include doctors, medical personnel, project managers, engineers, and academics who collaborate on its diagnostic solutions. The firm monetizes its R&D focus by providing specialized diagnostic tools and infrastructure services. Its products are designed for healthcare professionals and research institutions requiring advanced pathogen detection and antibiotic resistance analysis. By delivering both hardware systems like PCR ONE and BacterOMIC, and supporting services such as lab access and financing, Scope Fluidics SA serves the healthcare sector with tailored solutions for diagnostics and med-tech innovation. Scope Fluidics SA's revenue streams are derived from the sale of microfluidic systems, project support services, and access to its facilities. The company's target segments include medical professionals, researchers, and institutions engaged in diagnostic testing and antibiotic resistance studies. Its offerings combine hardware, software-free diagnostic tools, and collaborative infrastructure to address specific healthcare challenges in pathogen detection and treatment planning. Scope Fluidics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Scope Fluidics stock

Acquisitions (Net) of Scope Fluidics is 95.46 M PLN in 2024.

Acquisitions (Net) of Scope Fluidics changed from -9.88 M PLN to 95.46 M PLN, representing a -1,066.71% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Acquisitions (Net) Scope Fluidics since 2006 – with annual values, charts, and detailed analysis.

Net acquisitions represent the cash spent on acquiring other businesses, net of divestitures. Large acquisitions can transform a company's growth trajectory.

Acquisitions (Net)'s PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Acquisitions (Net)'s Scope Fluidics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Scope Fluidics

All Key Metrics — Scope Fluidics